If interested in learning more please call (602) 839-6500
Individuals between the ages of 47-68 who do not have a diagnosis of Alzheimer’s disease or memory problems and are in generally good physical and mental health are invited to participate in a screening visit for the study.
About The Study:
This longitudinal research program is designed to characterize the biological and cognitive changes that precede the onset of memory and thinking problems in people at different levels of genetic risk for Alzheimer’s disease.
This is a longitudinal study of adults aged 47-68 who are cognitively normal with two, one and no copies of the apolipoprotein E (APOE) ε4 allele, the major Alzheimer’s disease (AD) susceptibility gene. For nearly two decades, this study’s overriding goals have been to characterize the biomarker and cognitive measurements associated with preclinical AD and provide a foundation for the accelerated evaluation of promising prevention therapies. With the growing number of participants progressing to mild cognitive impairment (MCI) and dementia due to AD, we can now begin to characterize the extent to which different biomarker and cognitive measurements predict subsequent rates of clinical progression.
What Is Involved:
Healthy, qualified volunteers will receive a blood test. Some volunteers will be invited to have neurological and neuropsychological testing at Mayo Clinic and brain imaging (PET and MRI) at Banner Alzheimer's Institute every two years.